Iatrogenic (drug induced) cognitive disorders

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

This article discusses the clinical and pathogenetic aspects of iatrogenic (drug induced) cognitive disorders. It is emphasized that in most cases the etiology of these disorders is multifactorial in nature. In some cases, iatrogenic disorders are caused by the intake of an inadequately large dose of the drug, while in other cases, they are caused by the side effect of drugs. Disorders such as cerebral homeostasis, impaired permeability of the blood–brain barrier and the neurochemical properties of a certain drug are important. Side effects of drug therapy in elderly patients are much more common than in patients of a younger age, which is due to a number of causes, namely the poly-pragmasy characteristic of the elderly patients, erroneous prescription of certain drugs, drug interactions, altered pharmacokinetics and pharmacodynamics, and increased sensitivity to medications. Various groups of drugs are considered, during the intake of which, neuropsychiatric disorders may occur. In this case, special attention is paid to drugs with cholinolytic properties. Neurological disorders arising from radiation therapy were analyzed separately. It was concluded that it is necessary to assess the possible adverse effect of previously prescribed drug therapy for various indications in patients with cognitive impairment.

作者简介

Igor’ Damulin

Faculty of Continuing Medical Education “Medical Institute of People’s Friendship University of Russia”; I.M. Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: damulin@mmascience.ru
ORCID iD: 0000-0003-4826-5537

doctor of medical sciences, professor, Chief of the Department of Neurology and Neurosurgery with the Course of Complex Rehabilitation of the Faculty of Continuing Medical Education “Medical Institute of People’s Friendship University of Russia”; Professor of the Department of Nervous Diseases and Neurosurgery “I.M. Sechenov Moscow State Medical University (Sechenov University)”

俄罗斯联邦, Moscow

Alla Strutsenko

Faculty of Continuing Medical Education “Medical Institute of People’s Friendship University of Russia”; Medical Institute of People’s Friendship University of Russia

Email: Doctoralla08@rambler.ru
ORCID iD: 0000-0002-9758-8087

MD, PhD

俄罗斯联邦, Moscow

参考

  1. Marvanova M. Drug-induced cognitive impairment: effect of cardiovascular agents. Ment Health Clin. 2016;6(4):201-6. doi: 10.9740/mhc.2016.07.201.
  2. Stoner S.C. Drug-induced cognitive dysfunction. Medical Update for Psychiatrists. 1997;2(3):81-5. doi: 10.1016/s1082-7579(97)00004-6.
  3. Wahlund L.O., Basun H., Waldemar G. Reversible or arrestable dementias. In: Qizilbash N., Schneider L.S., Chui H. et al., eds. Evidence-based Dementia Practice. Oxford: Blackwell Sciences; 2002:330-40.
  4. Norrving B. An enigmatic encephalopathy. Pract Neurol. 2003;3(4): 248-50. doi: 10.1046/j.1474-7766.2003.11165.x.
  5. Mintzer J., Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93(9):457-62. doi: 10.1177/014107680009300903.
  6. Johnell K. Inappropriate drug use in people with cognitive impairment and dementia: a systematic review. Curr Clin Pharmacol. 2015;10(3):178-84. doi: 10.2174/1574884710666150609154741.
  7. Moore A.R., O’Keeffe S.T. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28. doi: 10.2165/00002512-199915010-00002.
  8. Geldmacher D.S., Whitehouse P.J. Evaluation of dementia. N. Engl. J. Med. 1996;335(5):330-6. doi: 10.1056/nejm199608013350507.
  9. Disorders of consciousness. In: Greenberg D.A., Aminoff M.J., Simon R.P. Clinical Neurology. 5th ed. New York: Lange Medical Books, McGraw-Hill; 2002:1-70.
  10. Berrios G.E, Markova I.S. Psychiatric disorders mimicking dementia. In: Hodges J.R., ed. Early-Onset Dementia. A Multidisciplinary Approach. Oxford: Oxford University Press; 2001:104-23.
  11. Grosset K.A., Grosset D.G. Prescribed drugs and neurological complications. J. Neurol. Neurosurg. Psychiatry. 2004;75(Suppl. 3):iii2-8. doi: 10.1136/jnnp.2004.045757.
  12. Keime-Guibert F., Napolitano M., Delattre J.Y. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11): 695-708. doi: 10.1007/s004150050271.
  13. Kurlan R., Como P. Drug-induced alzheimerism. Arch. Neurol. 1988; 45(3):356-7. doi: 10.1001/archneur.1988.00520270138035.
  14. Martin R., Kuzniecky R., Ho S., Pan J., Sinclair K., Gilliam F., Faught E. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52(2):321-7. doi: 10.1212/wnl.52.2.321.
  15. Mastaglia F.L. Iatrogenic (drug-induced) disorders of the nervous system. In: Aminoff M.J., ed. Neurology and General Medicine. The Neurological Aspects of Medical Disorders. 2nd ed. New York: Churchill Livingstone; 1995:587-614.
  16. Meador K.J., Loring D.W., Ray P.G., Murro A.M., King D.W., Perrine K.R. et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001;56(9):1177-82. doi: 10.1212/wnl.56.9.1177.
  17. Meador K.J., Loring D.W., Hulihan J.F., Kamin M., Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 2003;60(9):1483-8. doi: 10.1212/01.wnl.0000063308.22506.19.
  18. Stephens D.N., Dahlke F., Duka T. Consequences of drug and ethanol use on cognitive function. In: Moos W.H., Gamzu E.R., Thal L.J., eds. Cognitive Disorders: Pathophysiology and Treatment. New York: Marcel Dekker; 1992:159-81.
  19. Trojano L., Antonelli Incalzi R., Acanfora D., Picone C., Mecocci P., Rengo F. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol. 2003;250(12):1456-63. doi: 10.1007/s00415-003-0249-3.
  20. Kalaria R.N. The blood-brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci. 1999;893(1):113-25. doi: 10.1111/j.1749-6632.1999.tb07821.x.
  21. Katzman R. Epidemiology of Alzheimer’s disease and dementia: advances and challenges. In: Iqbal K., Sisodia S.S., Winblad B., eds. Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics. Chichester: John Wiley & Sons; 2001:11-21.
  22. Kivipelto M., Helkala E.L., Nissinen A., Soininen H., Tuomilehto J. Vascular risk factors, ApoE e4 allele, and gender and the risk of Alzheimer’s disease: perspectives on prevention. Drug Dev. Res. 2002; 56(2):85-94. doi: 10.1002/ddr.10064.
  23. Schmidt R., Schmidt H., Fazekas F. Vascular risk factors in dementia. J Neurol. 2000;247(2):81-7. doi: 10.1007/s004150050021.
  24. van Gool W.A., Eikelenboom P. The two faces of Alzheimer’s disease. J Neurol. 2000;247(7):500-5. doi: 10.1007/s004150070147.
  25. de la Torre J.C. Critically threshold cerebral hypoperfusion causes Alzheimer’s disease? Acta Neuropathol. 1999;98(1):1-8. doi: 10.1007/s004010051044.
  26. de la Torre J.C. Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer’s disease? Ann N Y Acad Sci. 2000; 903(1):424-36. doi: 10.1111/j.1749-6632.2000.tb06394.x.
  27. de la Torre J.C. Impaired cerebromicrovascular perfusion: summary of evidence in support of its causality in Alzheimer’s disease. Ann N Y Acad Sci. 2000;924(1):136-52. doi: 10.1111/j.1749-6632.2000.tb05572.x.
  28. de la Torre J.C., Stefano G.B. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutine nitric oxide. Brain Res Rev. 2000;34(3):119-36. doi: 10.1016/s0165-0173(00)00043-6.
  29. Farkas E., De Jong G.I., de Vos R.A., Jansen Steur E.N., Luiten P.G. Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease. Acta Neuropathol. 2000;100(4):395-402. doi: 10.1007/s004010000195.
  30. Farkas E., De Jong G.I., Apro E., De Vos R.A., Jansen Steur E.N., Luiten P.G. Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer’s disease, Parkinson’s disease, and experimental hypertension: what is the functional link? Ann N Y Acad Sci. 2000;903(1):72-82. doi: 10.1111/j.1749-6632.2000.tb06352.x.
  31. Blass J.P., Sheu R.K., Gibson G.E. Inherent abnormalities in energy metabolism in Alzheimer disease: interaction with cerebrovascular compromise. Ann N Y Acad Sci. 2000;903(1):204-21. doi: 10.1111/j.1749-6632.2000.tb06370.x.
  32. Prasad K.N., Cole W.C., Hovland A.R., Che Prasad K., Nahreini P., Kumar B. et al. Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr. Opin. Neurol. 1999;12(6):761-70. doi: 10.1097/00019052-199912000-00017.
  33. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K. et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-51. doi: 10.1136/bmj.322.7300.1447.
  34. Thompson P.J., Baxendale S.A., Duncan J.S., Sander J.W. Effects of topiramate on cognitive function. J. Neurol. Neurosurg. Psychiatry. 2000;69(5):636-41. doi: 10.1136/jnnp.69.5.636.
  35. Hamer H.M., Knake S., Schomburg U., Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54(1):230-2. doi: 10.1212/wnl.54.1.230.
  36. O’Neill M., Dubrey R.W., Grocott-Mason R.M. Valproate encephalopathy and hyperammonaemia. Postgrad Med J. 2002;78(919): 316-7. doi: 10.1136/pmj.78.919.316-a.
  37. Schwarz S., Georgiadis D., Schwab S., Gehlen F., Mayatepek E., Zoubaa S. Fulminant progression of hyperammonaemic encephalopathy after treatment with valproate in a patient with ureterosigmoidostomy. J. Neurol. Neurosurg. Psychiatry. 2002;73(1):90-1. doi: 10.1136/jnnp.73.1.90.
  38. Donaghy M. Toxic and environmental disorders of the nervous system. In: Walton J., ed. Brain’s Diseases of the Nervous System. 10th ed. Oxford: Oxford University Press; 1993:513-29.
  39. McShane R., Keene J., Gedling K., Fairburn C., Jacoby R., Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997;314(7076):266-72. doi: 10.1136/bmj.314.7076.266.
  40. Hoschl C., Hajek T. Hippocampal damage mediated by corticosteroids — a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci. 2001;251 Suppl 2:81-8. doi: 10.1007/bf03035134.
  41. Esiri M.M. Dementia due to other metabolic diseases and toxins. In: Esiri M.M., Morris J.H., eds. The Neuropathology of Dementia. Cambridge: Cambridge University Press; 1997:305-31.
  42. Filley C.M., Kleinschmidt-DeMasters B.K. Toxic leukoencephalopathy. N. Engl. J. Med. 2001;345(6):425-32. doi: 10.1056/nejm200108093450606
  43. Kunze K. Metabolic encephalopathies. J Neurol. 2002;249(9):1150-9. doi: 10.1007/s00415-002-0869-z.
  44. Benito-Leon J., Dominguez J. Kluver-Bucy syndrome in late delayed postirradiation encephalopathy. J Neurol. 1998;245(6-7):325-6. doi: 10.1007/s004150050227.
  45. Perrini P., Scollato A., Cioffi F., Mouchaty H., Conti R., Di Lorenzo N. Radiation leukoencephalopathy associated with moderate hydrocephalus: intracranial pressure monitoring and results of ventriculoperitoneal shunting. Neurol Sci. 2002;23(5):237-41. doi: 10.1007/s100720200048.
  46. Moretti R., Torre P., Antonello R.M., Cazzato G. Neuropsychological evaluation of late-onset, post-radiotherapy encephalopathy. Eur J Neurol. 2001;8(3):281-2. doi: 10.1046/j.1468-1331.2001.00211.x.
  47. Armstrong C.L., Hunter J.V., Ledakis G.E., Cohen B., Tallent E.M., Goldstein B.H. et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology. 2002;59(1): 40-8. doi: 10.1212/wnl.59.1.40.
  48. Walstra G.J.M., Teunisse S., van Gool W.A., van Crevel H. Reversible dementia in elderly patients referred to a memory clinic. J Neurol. 1996;244(1):17-22. doi: 10.1007/pl00007724.

版权所有 © Eco-Vector, 2020


 


##common.cookie##